Unit­ed’s Mar­tine Roth­blatt en­dors­es a biotech uni­corn’s CEO and antes up for US rights to an IPF drug

Unit­ed Ther­a­peu­tics Mar­tine Roth­blatt has joined the pack of ad­mir­ers back­ing one of the in­dus­try’s most in­trigu­ing biotech uni­corns.

Just a few months af­ter gain­ing a whop­ping $438 mil­lion round on a $12 bil­lion val­u­a­tion — with lit­tle hard da­ta to show so far — San Diego-based Sa­mumed is out­li­cens­ing an ear­ly-stage drug for id­io­path­ic pul­monary fi­bro­sis to Unit­ed for $10 mil­lion in cash and up to $340 mil­lion in mile­stones in a heav­i­ly back-end­ed deal.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER